Showing 1 - 7 results of 7 for search 'Axel H. Schönthal', query time: 0.04s Refine Results
  1. 1
    Endoplasmic Reticulum Stress: Its Role in Disease and Novel Prospects for Therapy

    Endoplasmic Reticulum Stress: Its Role in Disease and Novel Prospects for Therapy by Axel H. Schönthal

    Published 2012-01-01
    Get full text
    Article
  2. 2
    The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers

    The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers by Thomas C. Chen, Clovis O. da Fonseca, Daniel Levin, Axel H. Schönthal

    Published 2021-12-01
    Get full text
    Article
  3. 3
    Intranasal Delivery of miR133b in a NEO100-Based Formulation Induces a Healing Response in Spinal Cord-Injured Mice

    Intranasal Delivery of miR133b in a NEO100-Based Formulation Induces a Healing Response in Spinal Cord-Injured Mice by Camelia A. Danilov, Thu Zan Thein, Stanley M. Tahara, Axel H. Schönthal, Thomas C. Chen

    Published 2023-03-01
    Get full text
    Article
  4. 4
    Discovery of Cell Number-Interstitial Fluid Volume (CIF) Ratio Reveals Secretory Autophagy Pathway to Supply eHsp90α for Wound Healing

    Discovery of Cell Number-Interstitial Fluid Volume (CIF) Ratio Reveals Secretory Autophagy Pathway to Supply eHsp90α for Wound Healing by Cheng Chang, Xin Tang, Axel H. Schönthal, Mei Chen, David T. Woodley, Yanzhuang Wang, Chengyu Liang, Wei Li

    Published 2024-07-01
    Get full text
    Article
  5. 5
    Cytotoxic impact of a perillyl alcohol–temozolomide conjugate, NEO212, on cutaneous T-cell lymphoma

    Cytotoxic impact of a perillyl alcohol–temozolomide conjugate, NEO212, on cutaneous T-cell lymphoma by Catalina Silva-Hirschberg, Hannah Hartman, Samantha Stack, Steve Swenson, Radu O. Minea, Michael A. Davitz, Thomas C. Chen, Axel H. Schönthal

    Published 2019-12-01
    Get full text
    Article
  6. 6
    Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts

    Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts by Daniela A Bota, Jinah Chung, Manisha Dandekar, Jose A Carrillo, Xiao-Tang Kong, Beverly D Fu, Frank PK Hsu, Axel H Schönthal, Florence M Hofman, Thomas C Chen, Raphael Zidovetzki, Chrystel Pretto, Ankie Strik, Virgil EJC Schijns, Apostolos Stathopoulos

    Published 2018-07-01
    Get full text
    Article
  7. 7
    A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide

    A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolum... by Daniela A. Bota, Daniela A. Bota, Daniela A. Bota, Thomas H. Taylor, Thomas H. Taylor, Naomi Lomeli, Xiao-Tang Kong, Xiao-Tang Kong, Xiao-Tang Kong, Beverly D. Fu, Beverly D. Fu, Axel H. Schönthal, Samuel Singer, Deborah T. Blumenthal, Frank M. Senecal, Helena Linardou, Evangelos Rokas, Dimitris G. Antoniou, Virgil E. J. C. Schijns, Thomas C. Chen, Thomas C. Chen, Thomas C. Chen, Joseph Elliot, Apostolos Stathopoulos, Apostolos Stathopoulos, Apostolos Stathopoulos, Apostolos Stathopoulos

    Published 2022-06-01
    Get full text
    Article

Search Tools: